38766 Federal Register / Vol. 87, No. 124 / Wednesday, June 29, 2022 / Notices 

Dated: June 24, 2022. 

Diane Kreinbrink, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2022–13847 Filed 6–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Development of Radiation/ 

Nuclear Medical Countermeasures (MCMs) 

and Biodosimetry Devices. 

Date: July 28–29, 2022. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G42, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Sandip Bhattacharyya, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G42, 

Rockville, MD 20852, (240) 292–0189, 

sandip.bhattacharyya@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 23, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–13801 Filed 6–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the NIH Clinical Center 

Research Hospital Board. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify one of the Contact Persons listed 

below in advance of the meeting. The 

meeting can be accessed from the NIH 

videocast https://videocast.nih.gov/ and 

the CCRHB website https://ccrhb.

od.nih.gov/meetings.html. 

Name of Committee: NIH Clinical Center 

Research Hospital Board. 

Date: July 15, 2022. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: NIH and Clinical Center 

Leadership Announcements, Clinical Center 

(CC) CEO Update and CEO Status Report on 

2019 CC Strategic Plan, Role of the CC 

Patient Representative, Patient Survey Data, 

Magnet Journey Updates, and other Business 

of the Board. 

Place: National Institutes of Health, 

Building 31, Conference Room 6C02A/ 

C602B, 9000 Rockville Pike, Bethesda, MD 

20892. 

Contact Persons: Patricia Piringer, RN, 

MSN (C), National Institutes of Health 

Clinical Center, 10 Center Drive, Bethesda, 

MD 20892, ppiringer@cc.nih.gov, 301–402– 

2435, 202–460–7542 (direct). 

Natascha Pointer, Management Analyst, 

Executive Assistant to Dr. Gilman, Office of 

the Chief Executive Officer, National 

Institutes of Health Clinical Center, Bethesda, 

MD 20892, npointer@cc.nih.gov, 301–496– 

4114, 301–402–2434 (direct). 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

difficulties. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Persons listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures for entrance onto the NIH 

campus. All visitor vehicles, including 

taxicabs, hotel, and airport shuttles will be 

inspected before being allowed on campus. 

Visitors will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. In 

regards to COVID 19, please check 

community level guidelines (https://

ors.od.nih.gov/sr/dohs/safety/NIH-covid-19- 

safety-plan/Pages/default.aspx) and the Safer 

Federal Workforce for Visitors (https://

www.saferfederalworkforce.gov/faq/visitors/) 

websites before attending a meeting on NIH 

Main campus and any testing requirements. 

Please continue checking these websites, in 

addition to the committee website (https:// 

ccrhb.od.nih.gov/meetings.html), for the most 

up to date guidance as the meeting date 

approaches. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: June 24, 2022. 

Patricia B. Hansberger, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2022–13935 Filed 6–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Stimulating Access to 

Research in Residency (StARR) (R38 

Independent Clinical Trial Not Allowed). 

Date: July 19, 2022. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G45, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Vanitha S. Raman, Ph.D., 

Scientific Review Officer, Scientific Review 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 124 / Wednesday, June 29, 2022 / Notices 38767 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G45, Rockville, MD 

20852, 301–761–7949, vanitha.raman@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 23, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–13799 Filed 6–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director; Notice of Charter 

Renewal 

In accordance with title 41 of the U.S. 

Code of Federal Regulations, Section 

102–3.65(a), notice is hereby given that 

the Charter for the National Institutes of 

Health Clinical Center Research 

Hospital Board was renewed for an 

additional two-year period on June 15, 

2022. 

It is determined that the National 

Institutes of Health Clinical Center 

Research Hospital Board is in the public 

interest in connection with the 

performance of duties imposed on the 

National Institutes of Health by law, and 

that these duties can best be performed 

through the advice and counsel of this 

group. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or harriscl@mail.nih.gov. 

Dated: June 24, 2022. 

Patricia B. Hansberger, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2022–13931 Filed 6–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Project: Protection and Advocacy for 

Individuals with Mental Illness 

(PAIMI) Final Rule, 42 CFR Part 51 

(OMB No. 0930–0172)—Extension 

These regulations meet the directive 

under 42 U.S.C. 10826 (b) requiring the 

Secretary to promulgate final 

regulations to carry out the PAIMI Act 

(42 U.S.C. 10801 et seq.). The 

regulations contain information 

collection requirements. The Act 

authorizes funds to support activities on 

behalf of individuals with significant 

(severe) mental illness (adults) or 

significant (severe) emotional 

impairment (children/youth) as defined 

by the Act at 42 U.S.C. 10802 (4) and 

10804 (d). Only entities designated by 

the governor of each state, including the 

American Samoa, Guam, 

Commonwealth of the Northern Mariana 

Islands, Commonwealth of Puerto Rico, 

U.S. Virgin Islands, District of Columbia 

(Mayor), and the tribal councils of the 

American Indian Consortium (the Hopi 

Tribe and the Navajo Nation located in 

the Four Corners region of the 

Southwest), to protect and advocate the 

rights of persons with developmental 

disabilities are eligible to receive PAIMI 

Program grants [ibid at 42 U.S.C. at 

10802 (2)]. These grants are based on a 

formula prescribed by the Secretary 

[ibid at 42 U.S.C. at 10822 (a) (1) (A)]. 

On January 1, each eligible state 

protection and advocacy (P&A) system 

is required to prepare an annual PAIMI 

Program Performance Report (PPR). 

Each annual PPR describes a P&A 

system’s activities, accomplishments 

and expenditures to protect the rights of 

individuals with mental illness 

supported with payments from PAIMI 

program allotments during the most 

recently completed fiscal year. Each 

P&A system transmit a copy of its 

annual report to the Secretary (via 

SAMHSA) and to the State Mental 

Health Agency where the system is 

located per the PAIMI Act at 42 U.S.C. 

10824 (a). Each annual PPR must 

provide the Secretary with the following 

information: 

• The number of (PAIMI-eligible) 

individuals with mental illness served; 

• A description of the types of 

activities undertaken; 

• A description of the types of 

facilities providing care or treatment to 

which such activities are undertaken; 

• A description of the manner in 

which the activities are initiated; 

• A description of the 

accomplishments resulting from such 

activities; 

• A description of systems to protect 

and advocate the rights of individuals 

with mental illness supported with 

payments from PAIMI Program 

allotments; 

• A description of activities 

conducted by States to protect and 

advocate such rights; 

• A description of mechanisms 

established by residential facilities for 

individuals with mental illness to 

protect such rights; 

• A description of the coordination 

among such systems, activities and 

mechanisms; 

• Specification of the number of 

public and nonprofit P&A systems 

established with PAIMI Program 

allotments; and 

• Recommendations for activities and 

services to improve the protection and 

advocacy of the rights of individuals 

with mental illness and a description of 

the need for such activities and services 

that were not met by the state P&A 

systems established under the PAIMI 

Act due to resource or annual program 

priority limitations. 

Each PAIMI grantee’s annual PPR 

must include a separate section, 

prepared by its PAIMI Advisory Council 

(PAC), that describes the council’s 

activities and its assessment of the state 

P&A system’s operations per the PAIMI 

Act at 42 U.S.C. 10805 (7). 

In 2017, SAMHSA included the 

annual PAIMI PPR in the Web-based 

Block Grant Application System 

(WebBGAS). WebBGAS, SAMHSAs 

electronic data system, is used to collect 

grantee information for the following 

reasons: 

(1) To meet the OMB requirements for 

data collection for mandatory (formula) 

grant programs; 

(2) To comply with the annual 

program reporting requirements of the 

PAIMI Act 42 U.S.C. 10801 et seq. and 

the PAIMI Rules 42 CFR part 51; 

(3) To simplify the submission of 

PAIMI program data by the state P&A 

systems; 


lotter on DSK11XQN23PROD with NOTICES1